James Blachly, MDThe James Cancer Center
- Acute Myeloid Leukemias
- Chronic Lymphocytic Leukemias
- Hairy Cell Leukemia
I’m an oncologist focused on the treatment of patients diagnosed with Hairy Cell, Acute Myeloid, Acute Lymphocytic and Chronic Lymphocytic Leukemia. I’m a member of the Leukemia Research Program at the OSUCCC – James and serve as an assistant professor in Ohio State’s Division of Hematology.
My research interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics. My work explores whether and how mutations and transcriptional attributes can be studied in the context of clinical trials to provide prognostic and predictive information relevant to novel anticancer therapies.
I was recently named as one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation. I received a six-figure grant for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.”
I love the collaborative spirit at OSUCCC – James, and how we all share the common purpose of providing optimal and effective care and treatment for patients — and the goal of one day living in a world free of cancer.
Education and Background
University of Arkansas College of Medicine
Little Rock, AR
Ohio State University Wexner Medical Center
- American Board of Internal Medicine
- American Board of Internal Medicine (Subspecialty: Hematology)
- American Board of Internal Medicine (Subspecialty: Medicine Oncology)
- Department of Internal Medicine
- Division of Hematology
I see patients at
The James Cancer Hospital and Solove Research Institute
460 West 10th Avenue, Columbus, Ohio 43210
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 3/28/2017, Dr. Blachly has reported financial relationships with the medical device, research and/or drug companies listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office at 614-293-7802.